Product Name: TAO1 (306-312) pY309
Product Number: PE-04APX95
| Size: | 200 µg | Price: | 47.00 | |
| 1 mg | $US | 94.00 | ||
| 5 mg | 206.00 |
Peptide Name: TAO1 (306-312) pY309
Product Use: Services as a blocking peptide for use with the TAO1-pY309 rabbit polyclonal antibody (Cat. No.: AB-PK827) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located just after the kinase catalytic domain. Thhis is the major in vivo site of phosphorylation on TAO1.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: NLQ-pY-RKM
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Product Use: Services as a blocking peptide for use with the TAO1-pY309 rabbit polyclonal antibody (Cat. No.: AB-PK827) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located just after the kinase catalytic domain. Thhis is the major in vivo site of phosphorylation on TAO1.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: NLQ-pY-RKM
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1205.34 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: TAO1 - pY309 phosphosite-specific antibody (Cat. No.: AB-PK827)
Peptide Molecular Mass Calculated: 1205.34 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: TAO1 - pY309 phosphosite-specific antibody (Cat. No.: AB-PK827)
Scientific Background: TAO1 (MAP3K16, TAOK1) is a protein-serine/threonine kinase of the STE group and STE20 family. It is involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. It phosphorylates MAP2K3, MAP2K6 and MARK2, and acts as an activator of the p38 (MAPK14) stress-activated MAPK cascade by phosphorylation and activation of the upstream MKK3 and MKK6 kinases. It is involved in G protein-coupled receptor signalling to p38 (MAPK14). In response to DNA damage, it is involved in the G2/M transition DNA damage checkpoint by activating the p38 (MAPK14) stress-activated MAPK cascade, probably by mediating phosphorylation of MKK3 (MAP2K3) and MKK6 (MAP2K6). It serves as a regulator of cytoskeleton stability by phosphorylating MARK2 at T208, leading to its activation and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. It also regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the JNK (MAPK8) cascade.
© Kinexus Bioinformatics Corporation 2017